SCHEMBL5714539

SCHEMBL5714539

O=C(Oc1ccc2cccnc2c1)N1CCN(c2ccc(Cl)cn2)CC1

nearest known ligand 0.53

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 7/20 0.53
TRPV1 Q8NER1 6/20 0.49
PANK3 Q9H999 1/20 0.46
SCN9A Q15858 1/20 0.45
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
TSHR P16473 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HSD17B10 Q99714 1/20 0.43
SMO Q99835 1/20 0.43
MEN1 O00255 1/20 0.43
POLB P06746 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5714464 0.88 PANK3 (0.46) TRPA1TRPV1PANK3KDM4ESMO
SCHEMBL5715175 0.88 CHRM1 (0.49) TRPA1TRPV1PANK3ALDH1A1LMNA
SCHEMBL5714980 0.87 KMT2A (0.47) TRPA1TRPV1PANK3KDM4EALDH1A1
SCHEMBL5714487 0.86 KMT2A (0.58) KDM4EALDH1A1TSHRSMN1; SMN2HSD17B10
SCHEMBL5714858 0.85 HTT (0.59) TRPA1TRPV1SCN9AKDM4EALDH1A1
SCHEMBL5714535 0.84 HSD17B10 (0.42) TRPA1TRPV1PANK3KDM4EALDH1A1
SCHEMBL5715592 0.80 TRPA1 (0.47) TRPA1TRPV1ALDH1A1TSHRSMN1; SMN2
SCHEMBL28439784 0.79 ADORA2A (0.49) TRPA1TRPV1ALDH1A1TSHRSMN1; SMN2
SCHEMBL5715413 0.76 SCN9A (0.54) TRPA1TRPV1PANK3SCN9A
SCHEMBL5714360 0.76 TRPA1 (0.52) TRPA1TRPV1PANK3KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160819-A1 Substitued piperazine carbamates LIPE, PNLIP, LIPC TRPA1 2329/4885TRPV1 1675/4885PANK3 1247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.